Related Experiment Videos
The prospects for cancer gene therapy
C De Giovanni1, P Nanni, G Forni
1Institute for Cancer Research, University of Bologna, 40126, Bologna, Italy.
International Journal of Immunopharmacology
|January 4, 2001
Summary
Gene therapy for cancer shows promise by engineering immune cells or tumor cells to boost anti-tumor responses. This approach, particularly using engineered antigen-presenting cells (APCs), offers a viable strategy for cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Direct gene therapy for cancer faces challenges in effective in vivo delivery and overcoming tumor resistance.
- Immunological approaches offer an alternative by leveraging the immune system to combat cancer.
Purpose of the Study:
- To explore immunological strategies for cancer treatment using gene-modified cells.
- To evaluate the efficacy of engineered antigen-presenting cells (APCs) and tumor cells in generating anti-tumor immunity.
Main Methods:
- Engineering professional APCs with genes for tumor-associated peptides, costimulatory molecules, or cytokines.
- Modifying whole tumor cells to overexpress costimulatory and MHC molecules or secrete cytokines and chemokines.
- Assessing the anti-tumor immune response and therapeutic efficacy in preclinical models.
Main Results:
- Engineered APCs and tumor cells effectively recruit and activate APCs, skewing immune responses.
- Engineered tumor cells led to rapid rejection and immune memory development, even in poorly immunogenic tumors.
- Therapeutic efficacy was observed in established tumors and small metastases, but diminished with tumor progression.
Conclusions:
- Immunological gene therapy strategies, including engineered APCs and tumor cells, show significant potential for treating minimal or early-stage cancers.
- Further development is needed to overcome limitations in advanced tumor stages.
- The findings support the future use of cancer vaccines for both treatment and prevention.